Kerendia

Adult Dosing .

Dosage forms:  TAB: 10 mg, 20 mg, 40 mg

kidney disease progression and cardiovascular-associated risk reduction - DM type 2 patients with CKD

[20 mg PO qd]

Info: if K greater than 5.5 mEq/L, hold tx until K 5 mEq/L or less and restart at 10 mg/day, then after 4wk incr. to 20 mg/day if K 4.8 mEq/L or less and eGFR decr. <30%

heart failure-associated risk reduction - heart failure patients with LVEF >40%

[target dosing for patients with baseline eGFR >60]

Dose: 40 mg PO qd; Start: 20 mg PO qd, then after 4wk incr. to 40 mg PO qd if K less than 5 mEq/L and eGFR decr. <30%; Info: if K 5.5 to less than 6 mEq/L, decr. dose by 50%; if K 6 mEq/L or greater, hold tx until K less than 5-5.5 mEq/L and restart at 10 mg/day

[dose adjusted to 20 mg/day]

Dose: 20 mg PO qd; Info: if baseline eGFR >60, incr. dose to 40 mg PO qd after 4wk if K less than 5 mEq/L and eGFR decr. <30%; if K 5.5 to less than 6 mEq/L, decr. dose by 50%; if K 6 mEq/L or greater, hold tx until K less than 5-5.5 mEq/L and restart at 10 mg/day

[dose adjusted to 10 mg/day]

Dose: 10 mg PO qd; Info: incr. dose to 20 mg PO qd after 4wk if K less than 5 mEq/L and eGFR decr. <30%; if K 5.5 mEq/L or greater, hold tx until K less than 5-5.5 mEq/L and restart at 10 mg/day

renal dosing

[DM type 2-associated CKD]

eGFR 25-59: start 10 mg qd, then after 4wk incr. to 20 mg/day if K 4.8 mEq/L or less and eGFR decr. <30%; eGFR <25: avoid tx initiation

HD/PD: not defined

[heart failure with LVEF >40%]

eGFR 25-59: start 10 mg qd, then after 4wk incr. to target 20 mg/day if K less than 5 mEq/L and eGFR decr. <30%; eGFR <25: avoid tx initiation

HD/PD: not defined

hepatic dosing

[see below]

Child-Pugh Class C: avoid use

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.